ReShape Patent in Israel for Its Proprietary Diabetes Neuromodulation Tech

  ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company was granted a key international patent from the State of Israel Patent Office for its Diabetes Neuromodulation technology. Patent Number 277949, entitled, “Simultaneous Multi-Site Vagus Nerve Modulation for Improved Glycemic Control Systems and Methods,” will provide protection until December 4, 2039. The Diabetes Neuromodulation system utilizes its proprietary vagus nerve block (vBloc™) technology platform, combined with vagus nerve stimulation, for the treatment of Type 2 diabetes, a prominent disorder associated with obesity.

https://www.globenewswire.com/news-release/2025/02/03/3019532/0/en/ReShape-Lifesciences-Granted-Key-International-Patent-in-Israel-for-Its-Proprietary-Diabetes-Neuromodulation-Technology.html